A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary)
- Indications Colon cancer
- Focus Therapeutic Use
- 09 Sep 2021 Biomarkers information updated
- 07 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Mar 2013 Planned end date changed from 1 Apr 2011 to 1 Feb 2015 as reported by ClinicalTrials.gov.